Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate in rabbits
✍ Scribed by Heiko Iven; Helmut Brasch; Jörg Engster
- Publisher
- Springer
- Year
- 1985
- Tongue
- English
- Weight
- 551 KB
- Volume
- 15
- Category
- Article
- ISSN
- 0344-5704
No coin nor oath required. For personal study only.
✦ Synopsis
In rabbits the IV kinetics of MTX (1.33, 4 and 12 mg/kg) could be described by a linear three-compartment model with a terminal half-life between 2.4 and 3.6 h. During 8 h 50% of the dose was excreted into urine in unchanged form and 15% as the metabolite 7-OH-MTX. These fractions remained constant with increasing dose. In continuous infusion experiments (9-900 micrograms/kg X min MTX IV) a decrease of the renal MTX clearance with increasing plasma concentration was observed. This effect was nearly compensated by an increase of the extrarenal MTX clearance. After short-term infusion of 7-OH-MTX (4 mg/kg) a biexponential decline of 7-OH-MTX plasma concentrations was observed with a terminal half-life of 0.45 h. About 80% of the dose was regained from urine during 5 h. From the combined pharmacokinetic data a linear model was constructed for the calculation of 7-OH-MTX plasma concentrations after short-term MTX infusion. For the first 4 h after MTX application the predicted values were in good accordance with the 7-OH-MTX concentrations actually measured.
📜 SIMILAR VOLUMES
## Abstract The interaction between indomethacin (IND) and methotrexate (MTX) was investigated in rabbits. The study was designed so as to evaluate the effect of IND (1 mg h^−1^) during a continuous MTX infusion (1·2 mg kg^−1^) over 240 min. IND was injected i.v. at hourly intervals after a steady
The pharmacokinetics and tissue distribution of methotrexate (MTX) were investigated following intra-articular injection of either MTX solution or controlled release MTX loaded microspheres in healthy rabbit joints. MTX solution or MTX loaded microspheres (size 30-100 mm) (10 mg MTX) was injected in
The pharmacokinetics of methotrexate (MX) and 7-OH methotrexate (MXOH) was studied in 18 cancer patients treated with 6-hr intravenous (i.v.) infusion of 100 mglkg (A), 80 mglkg preceded by 20 mglkg i.v. loading dose (B), and 70 mg/kg preceded by 30 mglkg i.v. loading dose (C). Simultaneous analysis